Scholarlink

Background <p>Clinical and preclinical evidence suggests an association between higher levels of IL-6 and migraine. The present study aimed to determine whether pretreatment serum IL-6 levels were associated with headache outcomes at month 3 following migraine preventive treatment.</p> Methods <p>In this prospective study, newly diagnosed migraine patients without current or recent use of preventive medications within 3 months were recruited, and were dichotomized as having higher or lower IL-6 serum levels according to the median at baseline among all of the patients who started preventive treatment with flunarizine. Primary and secondary outcomes were the mean change from baseline in the number of monthly headache days (MHDs) at month 3 based on headache diaries, and the percentage of non-responders, i.e., patients without ≥ 50% MHD reduction at month 3 compared to baseline, respectively. Logistic regression analysis was performed to estimate the odds ratio (OR) and 95% confidence interval (CI) for the association between higher IL-6 levels and treatment non-response, which were further controlled for demographics, headache profiles, disability (measured by Migraine Disability Assessment), psychiatric comorbidities (measured by Hospital Anxiety and Depression Scale), and sleep quality (measured by Pittsburgh Sleep Quality Index).</p> Results <p>In total, 236 migraine patients (187&#xa0;F/49&#xa0;M, mean age ± standard deviation 37.1 ± 10.3 years) were analyzed. At baseline, the median IL-6 level was 0.79 pg/mL, and a higher IL-6 level was associated with an older age (mean age 39.5 ± 10.6 vs. 34.6 ± 9.5 years, <i>p</i> &lt; 0.001) and female sex (85.6% vs. 72.9%, <i>p</i> = 0.016), and a trend toward more MHDs (17.1 ± 8.1 vs. 15.0 ± 8.1 days/month, <i>p</i> = 0.050). After preventive treatment, patients with higher baseline IL-6 levels had less improvement in headache frequency (-5.7 vs. -8.2 MHDs, <i>p</i> = 0.004), and were more likely to be non-responders (72.0% vs. 44.9%, <i>p</i> &lt; 0.001) (adjusted OR = 2.90, 95% CI = 1.61–5.25, <i>p</i> &lt; 0.001). The results were consistent in sensitivity analysis across different subgroups.</p> Conclusions <p>There was an independent association between higher pretreatment IL-6 levels and poorer response to preventive treatment with flunarizine at month 3 in this large cohort of migraine patients. Whether this finding could be generalizable to other preventives and whether such patients could benefit from preventives of immunomodulatory properties need to be further explored.</p> Trial registration <p>ClinicalTrials.gov. NCT02747940, NCT04702971.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Higher Circulating IL-6 levels as a predictor for poor outcome after migraine preventive treatment: a prospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月10日

查看全文
  • Yen-Feng Wang,
  • Yi-Shiang Tzeng,
  • Li-Ling Hope Pan,
  • Yu-Hsiang Ling,
  • Shih-Pin Chen,
  • Wei-Ta Chen,
  • Kuan-Lin Lai,
  • Hung-Yu Liu,
  • Shuu-Jiun Wang

摘要

Background

Clinical and preclinical evidence suggests an association between higher levels of IL-6 and migraine. The present study aimed to determine whether pretreatment serum IL-6 levels were associated with headache outcomes at month 3 following migraine preventive treatment.

Methods

In this prospective study, newly diagnosed migraine patients without current or recent use of preventive medications within 3 months were recruited, and were dichotomized as having higher or lower IL-6 serum levels according to the median at baseline among all of the patients who started preventive treatment with flunarizine. Primary and secondary outcomes were the mean change from baseline in the number of monthly headache days (MHDs) at month 3 based on headache diaries, and the percentage of non-responders, i.e., patients without ≥ 50% MHD reduction at month 3 compared to baseline, respectively. Logistic regression analysis was performed to estimate the odds ratio (OR) and 95% confidence interval (CI) for the association between higher IL-6 levels and treatment non-response, which were further controlled for demographics, headache profiles, disability (measured by Migraine Disability Assessment), psychiatric comorbidities (measured by Hospital Anxiety and Depression Scale), and sleep quality (measured by Pittsburgh Sleep Quality Index).

Results

In total, 236 migraine patients (187 F/49 M, mean age ± standard deviation 37.1 ± 10.3 years) were analyzed. At baseline, the median IL-6 level was 0.79 pg/mL, and a higher IL-6 level was associated with an older age (mean age 39.5 ± 10.6 vs. 34.6 ± 9.5 years, p < 0.001) and female sex (85.6% vs. 72.9%, p = 0.016), and a trend toward more MHDs (17.1 ± 8.1 vs. 15.0 ± 8.1 days/month, p = 0.050). After preventive treatment, patients with higher baseline IL-6 levels had less improvement in headache frequency (-5.7 vs. -8.2 MHDs, p = 0.004), and were more likely to be non-responders (72.0% vs. 44.9%, p < 0.001) (adjusted OR = 2.90, 95% CI = 1.61–5.25, p < 0.001). The results were consistent in sensitivity analysis across different subgroups.

Conclusions

There was an independent association between higher pretreatment IL-6 levels and poorer response to preventive treatment with flunarizine at month 3 in this large cohort of migraine patients. Whether this finding could be generalizable to other preventives and whether such patients could benefit from preventives of immunomodulatory properties need to be further explored.

Trial registration

ClinicalTrials.gov. NCT02747940, NCT04702971.